Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Average Recommendation of “Moderate Buy” from Analysts

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $16.5714.

A number of research analysts have issued reports on FOLD shares. JPMorgan Chase & Co. lifted their target price on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. The Goldman Sachs Group lifted their price target on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Thursday, September 18th. Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th.

Amicus Therapeutics Trading Down 0.5%

Shares of FOLD stock opened at $9.90 on Friday. The stock’s fifty day moving average price is $8.94 and its two-hundred day moving average price is $7.51. The company has a market cap of $3.05 billion, a PE ratio of -247.44 and a beta of 0.46. Amicus Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $10.57. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.The company had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. During the same quarter in the previous year, the firm earned $0.10 EPS. Amicus Therapeutics’s revenue was up 19.5% on a year-over-year basis. Equities analysts predict that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In related news, insider Ellen Rosenberg sold 23,621 shares of the business’s stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $10.00, for a total transaction of $236,210.00. Following the sale, the insider owned 507,710 shares in the company, valued at $5,077,100. The trade was a 4.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jeff Castelli sold 76,158 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $10.16, for a total value of $773,765.28. Following the completion of the transaction, the insider directly owned 439,318 shares of the company’s stock, valued at approximately $4,463,470.88. The trade was a 14.77% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 216,239 shares of company stock worth $2,165,304. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Allworth Financial LP boosted its position in Amicus Therapeutics by 36.3% during the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,246 shares during the period. Swiss Life Asset Management Ltd bought a new position in shares of Amicus Therapeutics during the third quarter valued at $83,000. CIBC Bancorp USA Inc. acquired a new position in shares of Amicus Therapeutics during the third quarter worth $234,000. Sender Co & Partners Inc. bought a new stake in shares of Amicus Therapeutics in the third quarter worth $272,000. Finally, PharVision Advisers LLC bought a new stake in shares of Amicus Therapeutics in the third quarter worth $95,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.